NUWE News & Events

Reports Q4 revenue $2.424M vs $2.322M last year. "2025 was a year of structural change and strategic re-focus for Nuwellis," said John Erb, Chief Executive Officer of Nuwellis. "While full year revenue declined compared to 2024, fourth quarter results reflected stronger utilization trends and meaningful gross margin expansion. Throughout the year, we prioritized operational discipline, refined our commercial focus around the cardiorenal continuum, and strengthened the underlying foundation of the business."

Nuwellis announced the appointment of Stuart Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine.

Nuwellis announced the appointment of David McDonald and Martin Emerson to its Board of Directors, effective February 24, 2026. Emerson currently serves as President and Chief Executive Officer of Monteris Medical. McDonald serves as Vice Chairman Healthcare Investment Banking at Lake Street Capital Markets and brings more than 25 years of experience in healthcare capital markets and corporate development..

Nuwellis files to sell 4.28M shares of common stock for holders